Nothing Special   »   [go: up one dir, main page]

NL300746I1 - - Google Patents

Info

Publication number
NL300746I1
NL300746I1 NL300746C NL300746C NL300746I1 NL 300746 I1 NL300746 I1 NL 300746I1 NL 300746 C NL300746 C NL 300746C NL 300746 C NL300746 C NL 300746C NL 300746 I1 NL300746 I1 NL 300746I1
Authority
NL
Netherlands
Application number
NL300746C
Other versions
NL300746I2 (nl
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300746(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NL300746I2 publication Critical patent/NL300746I2/nl
Publication of NL300746I1 publication Critical patent/NL300746I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL300746C 2002-04-16 2015-06-29 NL300746I1 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
PCT/US2003/011510 WO2003089428A1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (2)

Publication Number Publication Date
NL300746I2 NL300746I2 (nl) 2016-01-21
NL300746I1 true NL300746I1 (nl) 2016-01-21

Family

ID=29250954

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300746C NL300746I1 (nl) 2002-04-16 2015-06-29

Country Status (34)

Country Link
US (3) US7304078B2 (nl)
EP (5) EP2065384B1 (nl)
JP (2) JP4558331B2 (nl)
KR (1) KR101026929B1 (nl)
CN (1) CN1659162B (nl)
AR (1) AR039570A1 (nl)
AT (3) ATE455774T1 (nl)
AU (1) AU2003221932B2 (nl)
BR (1) BRPI0309309B8 (nl)
CA (1) CA2482858C (nl)
CY (3) CY1107184T1 (nl)
DE (3) DE60331114D1 (nl)
DK (2) DK1495018T3 (nl)
EC (1) ECSP045368A (nl)
ES (3) ES2297150T7 (nl)
FR (1) FR15C0047I2 (nl)
HK (3) HK1070887A1 (nl)
IL (1) IL164585A (nl)
LT (1) LTC1495018I2 (nl)
LU (1) LU92759I2 (nl)
MX (1) MXPA04010308A (nl)
MY (1) MY144040A (nl)
NL (1) NL300746I1 (nl)
NO (2) NO330500B1 (nl)
NZ (2) NZ575139A (nl)
PE (1) PE20040412A1 (nl)
PL (1) PL214718B1 (nl)
PT (2) PT2065384E (nl)
RU (2) RU2329264C9 (nl)
SG (1) SG164279A1 (nl)
SI (2) SI2065384T1 (nl)
TW (1) TWI343919B (nl)
WO (1) WO2003089428A1 (nl)
ZA (1) ZA200408342B (nl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
MXPA06013903A (es) * 2004-05-28 2007-01-26 Schering Corp Analogos restringidos de himbacina como antagonistas del receptor de trombina.
US8563511B2 (en) * 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
EP2399912B1 (en) * 2005-01-14 2015-02-25 Merck Sharp & Dohme Corp. An exo-selective synthesis of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
PT2206697E (pt) * 2005-01-14 2012-01-10 Schering Corp Sínteses exo- e diastereosselectivas de análogos da himbacina
CN101137614A (zh) * 2005-01-14 2008-03-05 先灵公司 喜巴辛类似物的手性炔丙醇和酯中间体的制备
AR052870A1 (es) * 2005-01-14 2007-04-11 Schering Corp Sintesis de analogos de himbacina
KR20070116066A (ko) * 2005-03-31 2007-12-06 쉐링 코포레이션 스피로사이클릭 트롬빈 수용체 길항제
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
BRPI0620641A2 (pt) * 2005-12-22 2011-11-16 Schering Corp usos de compostos antagonistas de receptor de trombina na profilaxia de complicações de cirurgia cardiopulmonar
AR060354A1 (es) * 2006-04-06 2008-06-11 Schering Corp Terapias de combinacion antagonistas receptor trombina (tra)
US8003803B2 (en) * 2006-04-13 2011-08-23 Schering Corporation Fused ring thrombin receptor antagonists
EP2032560B1 (en) * 2006-06-29 2013-05-01 Merck Sharp & Dohme Corp. Substituted bicyclic and tricyclic thrombin receptor antagonists
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
JP2010505842A (ja) 2006-10-04 2010-02-25 シェーリング コーポレイション トロンビン受容体拮抗薬としての二環式誘導体および三環式誘導体
JP2010505836A (ja) * 2006-10-04 2010-02-25 シェーリング コーポレイション ヒンバシンの修飾された三環単位に基づいたトロンビン受容体アンタゴニスト
MX2009006873A (es) * 2006-12-22 2009-07-03 Schering Corp Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida.
MX2009010268A (es) * 2007-03-23 2009-11-09 Schering Corp Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
NZ587141A (en) 2008-02-05 2012-04-27 Sanofi Aventis Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MY148732A (en) 2008-02-05 2013-05-31 Sanofi Aventis Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
AR071823A1 (es) 2008-05-19 2010-07-14 Schering Corp Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos.
JP5789256B2 (ja) 2009-06-04 2015-10-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． トロンビン受容体アンタゴニストの活性代謝物
JP2012529431A (ja) 2009-06-08 2012-11-22 メルク・シャープ・アンド・ドーム・コーポレーション トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤
AR077695A1 (es) 2009-08-04 2011-09-14 Schering Corp Derivados de pirimidina como inhibidores del factor ixa
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
ES2527535T3 (es) 2010-04-16 2015-01-26 Sanofi Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
US9340530B2 (en) 2012-03-06 2016-05-17 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as PAR-1 receptor antagonists
EP3024550A4 (en) * 2013-07-22 2016-12-07 Merck Sharp & Dohme CO-CRYSTAL OF VORAPAXAR PAR-1 RECEPTOR ANTAGONIST AND ASPIRINE
WO2015026685A1 (en) * 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives
EP3035929B1 (en) * 2013-08-22 2024-07-03 Merck Sharp & Dohme LLC 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives
EP3035928B1 (en) 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
US20230312560A1 (en) 2020-07-22 2023-10-05 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
BR9812793A (pt) * 1997-11-25 2000-10-17 Schering Corp Antagonistas do receptor de trombina
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
HUP0303081A3 (en) * 2000-06-15 2009-03-30 Schering Corp Thrombin receptor antagonists, pharmaceutical compositions containing them and their use
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
NZ531869A (en) 2001-10-18 2006-11-30 Schering Corp Himbacine analogues as thrombin receptor antagonists

Also Published As

Publication number Publication date
AR039570A1 (es) 2005-02-23
EP2065384B1 (en) 2011-01-05
NL300746I2 (nl) 2016-01-21
DE60335679D1 (de) 2011-02-17
ZA200408342B (en) 2006-05-31
CA2482858A1 (en) 2003-10-30
PT2065384E (pt) 2011-03-16
JP2010132710A (ja) 2010-06-17
PL214718B1 (pl) 2013-09-30
SG164279A1 (en) 2010-09-29
IL164585A (en) 2010-11-30
EP1860106B1 (en) 2010-01-20
US20070179187A1 (en) 2007-08-02
LU92759I2 (en) 2015-08-31
RU2329264C9 (ru) 2009-04-20
CY2015029I1 (el) 2016-04-13
ES2297150T7 (es) 2012-03-16
NZ535880A (en) 2007-11-30
RU2008106401A (ru) 2009-08-27
NO2015016I2 (no) 2015-07-09
EP1495018B3 (en) 2011-03-16
HK1070887A1 (en) 2005-06-30
EP2065384A1 (en) 2009-06-03
RU2004133375A (ru) 2005-07-10
CN1659162A (zh) 2005-08-24
ES2297150T3 (es) 2008-05-01
AU2003221932B2 (en) 2007-11-22
IL164585A0 (en) 2005-12-18
EP2062890B1 (en) 2011-01-05
DE60331114D1 (de) 2010-03-11
EP1495018A1 (en) 2005-01-12
EP1495018B1 (en) 2007-11-14
US20070270439A1 (en) 2007-11-22
KR20040099441A (ko) 2004-11-26
PT1495018E (pt) 2008-02-19
DK2065384T3 (da) 2011-05-02
MY144040A (en) 2011-07-29
ES2357876T3 (es) 2011-05-03
RU2329264C2 (ru) 2008-07-20
EP1860106A1 (en) 2007-11-28
US7713999B2 (en) 2010-05-11
ES2338171T3 (es) 2010-05-04
ATE378330T1 (de) 2007-11-15
NO20044963L (no) 2004-11-15
US7304078B2 (en) 2007-12-04
JP2005528406A (ja) 2005-09-22
US20030216437A1 (en) 2003-11-20
DE60317493T2 (de) 2008-09-18
EP1982984A3 (en) 2008-10-29
NO2015016I1 (no) 2015-07-20
CN1659162B (zh) 2011-08-31
DK1495018T3 (da) 2008-02-18
ATE455774T1 (de) 2010-02-15
BRPI0309309B8 (pt) 2021-05-25
SI2065384T1 (sl) 2011-05-31
HK1129893A1 (en) 2009-12-11
FR15C0047I2 (fr) 2016-05-06
CY2015029I2 (el) 2016-04-13
JP4558331B2 (ja) 2010-10-06
DE60317493D1 (en) 2011-01-13
ATE494284T1 (de) 2011-01-15
TWI343919B (en) 2011-06-21
CY1107184T1 (el) 2012-10-24
NO330500B1 (no) 2011-05-02
LTC1495018I2 (lt) 2017-04-10
HK1123302A1 (en) 2009-06-12
ECSP045368A (es) 2005-01-03
PE20040412A1 (es) 2004-07-12
AU2003221932A1 (en) 2003-11-03
NZ575139A (en) 2010-08-27
TW200404068A (en) 2004-03-16
FR15C0047I1 (nl) 2015-08-28
SI1495018T1 (sl) 2008-04-30
EP1982984B1 (en) 2013-02-13
BRPI0309309B1 (pt) 2018-09-04
CA2482858C (en) 2010-11-30
DE60317493T3 (de) 2018-07-12
MXPA04010308A (es) 2005-02-03
EP2062890A1 (en) 2009-05-27
BR0309309A (pt) 2005-02-15
PL373332A1 (en) 2005-08-22
EP1982984A2 (en) 2008-10-22
CY1111363T1 (el) 2015-08-05
KR101026929B1 (ko) 2011-04-04
WO2003089428A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
BE2019C547I2 (nl)
BE2019C510I2 (nl)
BE2018C021I2 (nl)
BE2017C049I2 (nl)
BE2017C005I2 (nl)
BE2016C069I2 (nl)
BE2016C040I2 (nl)
BE2016C013I2 (nl)
BE2018C018I2 (nl)
BE2016C002I2 (nl)
BE2015C078I2 (nl)
FR15C0047I1 (nl)
BE2015C017I2 (nl)
BE2014C053I2 (nl)
BE2014C051I2 (nl)
BE2014C041I2 (nl)
BE2014C030I2 (nl)
BE2014C016I2 (nl)
BE2014C015I2 (nl)
BE2015C067I2 (nl)
IN2007CH00077A (nl)
JP2003045657A5 (nl)
JP2002286591A5 (nl)
BRPI0215435A2 (nl)
JP2003234911A5 (nl)